Key prospective trials evaluating PET response-adapted approaches are summarized in Table 3.27-29, TABLE 3. In the initial CheckMate 039 trial, 23 patients with HL who progressed post-ASCT (78%) or BV (78%) were treated with nivolumab; a high ORR of 87% and PFS of 86% at 24 weeks was demonstrated.68 Nivolumab was approved based on the CheckMate 205 trial, in which 243 patients with relapsed/refractory HL who had failed ASCT were treated with nivolumab monotherapy, with an ORR of 69%, a CR of 16%, and overall median PFS of 15 months. Hodgkin lymphoma that recurs after ASCT usually cannot be cured but can be very usefully palliated with new agents such as brentuximab vedotin and the checkpoint inhibitors nivolumab and pembrolizumab.  |  Importantly, the guidelines refer to patients naïve to PARP inhibitors. For PET-negative patients, the final analysis confirmed that CMT resulted in a substantial improvement in 5-year PFS by 12% in favorable risk patients (HR 15.8; 95% CI, 3.79–66.07) and 3% for unfavorable risk patients (HR 1.45; 95% CI, 0.84–2.50).27 For PET-positive patients, 5-year PFS was 13% greater with intensified therapy compared with standard therapy with ABVD (HR 0.42; 95% CI, 0.23–0.74; p = .002). Accessed August 28, 2020. https://finance.yahoo.com/news/american-society-clinical-oncology-exclusively-110500791.html, Clinical Consult: Assessing the Impact of Tailor X. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc. Journal of Clinical Oncology. Analysis of the response time to involved-field radiotherapy in primary gastrointestinal low-grade B-cell lymphoma. In PET-positive patients, chemotherapy was intensified to 2× escalated BEACOPP followed by 30 Gy INRT. © 2020 MJH Life Sciences™ and . Editorial Roster Clinicians treating patients with Hodgkin lymphoma now have access to novel treatment approaches, which will require detailed assessment of each patient and careful discussion of the goals and risks of treatment at the time of planning primary treatment, again during delivery of that treatment as data indicating ongoing effectiveness become available, at the conclusion of initial intervention, and, when the need arises, at the time of recurrence of disease. All rights reserved. JCO Precision Oncology, ASCO Educational Book These heavily pretreated patients were divided into three cohorts according to their BV status, with a slightly higher CR rate for the patients not previously treated with BV as compared with patients who received BV before or after ASCT (29% vs. 12% and 13%, respectively).69 Pembrolizumab was approved based on the KEYNOTE-87 trial that divided 210 patients with relapsed/refractory HL into three cohorts according to previous treatment with ASCT and/or BV, with all three cohorts showing an ORR of 69% and a CR of 22%.70. NIH This report presents an effort by the International Lymphoma Radiation Oncology Group (ILROG) to harmonize and standardize the principles of treatment of ENL, and to address the technical challenges of simulation, volume definition and treatment planning for the most frequently involved organs. Get the latest research from NIH: https://www.nih.gov/coronavirus. However, for the approximately 20% of patients with a positive interim PET, the impact of a growing body of evidence suggests that the negative prognostic impact of a positive interim PET can be at least partially overcome by switching to intensified treatment such as escalated BEACOPP after a positive interim PET. Authors: E. Zucca, L. Arcaini, C. Buske, P.W. ASCO Career Center Additionally, treatment with a PARP inhibitor should be offered to patients with recurrent EOC that has not recurred within 6 months of platinum-based therapy, who have not received a PARP inhibitor, and have a germline or somatic BRCA1/2, or whose tumor demonstrates genomic instability, according to ASCO. About This switch to intensified treatment may as much as double 2- to 3-year failure-free survival (Table 7).